The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | ASH highlights: groundbreaking results from the TEAMM trial
Despite the controversy surrounding the design of the Tackling EArly Morbidity and Mortality in Myeloma (TEAMM) trial (ISRCTN51731976), a Phase III randomized study that assessed the benefit of antibiotic prophylaxis and its effect on healthcare-associated infections in patients with multiple myeloma (MM), follow-up results have shown that patients do benefit from the therapy. Here, Martin Kaiser, MD, of The Royal Marsden Hospital NHS Foundation Trust, London, UK, shares his thoughts on the trial, which was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
